RxDoctor Payments Data

John Paguntalan, NP

Nurse Practitioner · Greenwood, SCNPI 1669664728

Payments from drug & device makers

$2,993in general payments, 2019–2025

Across 121 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$465
  • Novartis$289
  • E.r. Squibb & Sons, L.L.C.$286
  • Johnson & Johnson$233
  • Merck$196
  • Boehringer Ingelheim$179
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,993100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,993 in reported general payments places this provider in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$58,646
Medicare patients
546
Services billed
1,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban395$363,472
JardianceEmpagliflozin137$106,902
EntrestoSacubitril/Valsartan85$70,134
XareltoRivaroxaban47$37,648
MultaqDronedarone Hcl19$14,913
Metoprolol Succinate565$10,350
Dofetilide62$7,107
Amiodarone Hcl249$4,114
Flecainide Acetate66$2,219
Potassium Chloride109$2,070
Diltiazem 24hr Er (Cd)Diltiazem Hcl50$1,355
Losartan Potassium158$1,329
Atorvastatin Calcium151$1,323
Enoxaparin Sodium11$1,059
Bumetanide34$1,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$110$363,472395 claims
Boehringer IngelheimJardiance$179$106,902137 claims
NovartisEntresto$289$70,13485 claims
Johnson & JohnsonXarelto$233$37,64847 claims
Sanofi-aventis U.S. LLCMultaq$15$14,91319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Greenwood

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →